Acalabrutinib 100 mg is a targeted therapy used to treat chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL). It works by blocking Bruton’s tyrosine kinase (BTK) to slow cancer cell growth. Common side effects may include headache, fatigue, diarrhea, muscle pain, bruising, and upper respiratory infections. Active Ingredient (Generic Name): Acalabrutinib Indication: Blood Cancer Manufacturer: Natco Pharma Ltd. Packaging: 30 capsules in 1 bottle Strength 100mg Delivery Time: 6 To 15 days


Abraxane 100 Mg Injection
Bicalutamide 50 mg Tablet Australia
Acabrunat 100 mg (Acalabrutinib)